E ndovascular therapy (ET) is an increasingly used therapeutic strategy in acute ischemic stroke.
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March 2015 staining (CS) or brain hemorrhage after ET in a cohort of patients studied with DE-CT.
Materials and Methods
Patients
Patients were part of a prospectively collected registry of acute ischemic stroke treated with ET at a single Comprehensive Stroke Center. A total of 203 patients were treated from May 2010 to June 2013, of whom 132 who were evaluated with a DE-CT scan after ET were included in the study. A contemporary group of 71 patients was not included because DE-CT was not performed (n=46 because of DE-CT equipment unavailability, n=7 because of early clinical deterioration resulting in death before post-ET neuroimaging, and n=18 because of preference for brain MRI). According to our institutional protocol, the patients and their legal representatives signed a written informed consent accepting to receive ET and to be included in the registry. The study protocol was approved by the local Clinical Research Ethics Committee.
All treated patients had a CT angiography that confirmed a proximal artery occlusion and ruled out a malignant profile, as previously reported. 18 In patients with symptoms lasting >4.5 hours, the presence of mismatch was also required. Type (primary or rescue therapy after systemic thrombolysis), duration of the interventional procedure, and final vessel patency were prospectively recorded. Iopromide (Ultravist, Bayer HealthCare Pharmaceuticals; 300 mgI/mL; molecular weight, 791.12 Da), a low-osmolar nonionic monomeric x-ray contrast medium, was used for the therapeutic angiographic procedures. Final vessel patency was graded on digital subtraction angiography according to the thrombolysis in cerebral infarction classification (grade 0, no perfusion; grade 1, penetration with minimal perfusion; grade 2a, partial filling of the entire vascular territory; grade 2b, complete filling, but the filling is slower than normal; grade 3, complete perfusion). Recanalization was defined as complete if a 2b-3 grade was obtained at the end of ET.
After the procedure, patients were admitted into an intermediate care Stroke Unit. Demographics, neuroimaging data, concomitant therapies, clinical course, and functional outcome were prospectively collected. The Alberta Stroke Program Early CT Score was assessed on baseline CT, and qualifying strokes were classified according to the Trial of Org 10 172 in Acute Stroke Treatment (TOAST) criteria. Functional outcome was scored with the modified Rankin Scale at 3 months, and poor outcome was defined as a modified Rankin Scale score >2.
DE-CT Imaging and Follow-Up Imaging Studies
According to our protocol for endovascular procedures, a complete postinterventional DE-CT data set was acquired after ET. Images were obtained through a 64-channel multidetector dual-source CT equipment (Somatom Definition FLASH; Siemens), which uses 2 xray tubes optimized independently and 2 stellar detectors in the same gantry. The implemented protocol allowed simultaneous imaging acquisition at 100 kV/250 mAs and 140 kV/250 mAs, and a 20×0.6 mm collimation (total dose ≈3 mSv effective, similar to that required for single source CT). The information obtained was rebuilt in 3 different series, 2 sets corresponding to 100 and 140 kV, respectively (slice thickness of 1.5 mm), and a third set corresponding to a mixture map of both energies (100 kV/140 kV) simulating a conventional CT of 120 kV. Subsequent postprocessing was performed through commercial software (syngo.CT Dual-Energy Brain Hemorrhage; Siemens). The software uses a 3-material decomposition algorithm aimed to differentiate normal brain parenchyma, hemorrhage, and iodine contrast to finally obtain an iodine map (for displaying only iodine) and a virtual noncontrast map (to visualize brain parenchyma and hemorrhage). Iodine maps and virtual noncontrast maps were used to differentiate between high attenuation areas related to CS alone and to brain hemorrhage in concordance with previously published data, as shown in Figure 1 .
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Follow-up imaging by CT/MRI angiography was performed at 48 to 72 hours of stroke in 110 patients. Bleeding complications were defined on brain imaging according to the European Cooperative Acute Stroke Study criteria as hemorrhagic infarction and parenchymal hematoma type 1 and parenchymal hematoma type 2. Investigators blinded to clinical data evaluated DE-CT, and investigators blinded to DE-CT group classification evaluated follow-up imaging studies and modified Rankin Scale.
Statistics
Continuous variables were reported as mean (SD) or median (interquartile range) and were compared with the Student t test, ANOVA, Figure 1 . Dual-energy computed tomographic (CT) classification of parenchymal high attenuation areas after endovascular therapy. High attenuation areas were defined as areas with higher density than the normal white matter or surrounding gray matter in plain CT. Absence high attenuation areas in plain CT (A). A hyperattenuation only seen on the iodine overlay image was classified as contrast staining alone (B); a hyperattenuation only seen on the virtual noncontrast (VNC) maps was classified as hemorrhage (C). When contrast staining and brain hemorrhages were found together, the patient was classified in the brain hemorrhage group (C).
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Mann-Whitney, or Kruskal-Wallis tests as appropriate. Categorical variables were compared with the χ2 and Fisher exact tests. Multivariate logistic regression analyses adjusted for variables with a P<0.10 on univariate analysis were built to assess the value of DE-CT groups to predict the bleeding risk and the functional outcome at 90 days, using a conditional forward procedure. Age, type of ET (primary versus rescue), and time from symptom onset to recanalization (when applicable) were forced in the final models used for prediction of clinical outcomes for their prognostic relevance; time from ET conclusion to DE-CT acquisition was also forced because of the significant imbalance between groups. The analysis was performed using SPSS Version 19.0 and the level of significance was established at the 0.05 level (2-sided) .
Results
Main Characteristics of the Study Population
Overall, 132 patients were included in the analysis, of whom 53 (40%) had no high attenuated areas after ET (no-HA group), 32 (24%) disclosed CS alone (CS group), and 47 (36%) disclosed brain hemorrhage or a combination of hemorrhage and CS (BH group). Descriptive data on demographics and baseline variables according to DE-CT classification are shown in Table 1 . Of note, CS and BH groups disclosed a higher proportion of use of antithrombotics before admission, lower baseline Alberta Stroke Program Early CT Score, longer time from stroke onset to recanalization, and shorter delays to DE-CT acquisition, in comparison with no-HA group. High attenuated subarachnoid areas were exclusively observed in CS and BH groups and were classified as subarachnoid hemorrhage only in the BH group.
The location of arterial occlusions before ET, the modality of ET (rescue versus primary ET), and the type of ET techniques were similar across DE-CT-defined groups, as shown in Table 1 . Of note, the most widely used thrombectomy (14) 68 (13) 65 (14) 0.612
Men, n (%) 26 (49) 18 (56) 19 (40) 0.373
Hypertension, n (%) 32 (60) 17 (53) 28 (60) 0.787
Diabetes mellitus, n (%) 14 (26) 5 (16) 10 (21) 0.503
Atrial fibrillation, n (%) 14 (26) 11 (34) 16 (34) 0.640
Previous antithrombotic treatment, n (%) 24 (45) 10 (31) 27 (57) 0.071
Baseline SBP, mean (SD), mm Hg 146 (23) 145 (23) 149 (25) (93) 29 (91) 44 (94) 0.885
Merci device, n (%) 7 (13) 1 (3) 2 (4) 0.132
Local alteplase, n (%) 0 (0) 1 (3) 1 (2) 0.475
Device passes per procedure, median (IQR)
Recanalization 2b-3 (yes), n (%) 46 (87) 26 (81) devices were stent retrievers (92%). The duration of the endovascular procedure and the number of device passes were highly correlated (Spearman ρ, 0.643; P<0.001), and both variables were significantly higher in CS and BH groups (Table 1) .
Clinical Outcomes After ET According to DE-CTDefined Groups
Poor outcome at 90 days occurred in 67 (51%) patients and was associated with increased baseline stroke severity, higher glucose, and systolic blood pressure levels at baseline, hypertension, diabetes mellitus, absence of recanalization, and duration of ET procedure ( (Table 2) . Moreover, more patients with CS or BH shifted into worse categories of the modified Rankin Scale using ordinal regression analysis (Table 2) .
Complete recanalization was obtained in 109 (83%) patients, although in 50 (46%) patients it was not followed by good outcome. Poor outcome despite complete recanalization was associated with higher baseline National Institutes of Health Stroke Scale, primary ET, hypertension, diabetes mellitus, baseline glucose levels, and baseline systolic blood pressure in univariate analyses (Table II in the online-only Data Supplement). The rate of poor outcome despite complete recanalization was significantly higher in CS (58%; OR, 4.91; 95% CI, 1.72-13.99) and BH (68%; OR, 7.50; 95% CI, 2.81-20.03) compared with the no-HA group (22%) in univariate analysis, and this association remained significant also in multivariate regression models (Table 2) .
CS After ET and the Risk of Delayed Hemorrhagic Transformation
Overall, hemorrhagic transformation (HT) was seen in 55 (50%) patients, of whom 27 (25%) had hemorrhagic infarction and 28 (26%) had parenchymal hematoma. The presence of HT at follow-up neuroimaging was significantly associated with baseline Alberta Stroke Program Early CT Score, prior antithrombotic treatment, and cardioembolic pathogenesis and was also marginally associated with poor prognosis (58%, versus 40%; P=0.056).
Delayed HT was evaluated in 71 patients without signs of brain hemorrhage as classified by DE-CT after ET, of whom 44 pertained to the non-HA group and 27 to the CS group. In this subset of patients, the use of antithrombotics after DE-CT did not differ between CS and no-HA groups (data not shown), and was neither associated with delayed HT (Table III in the online-only Data Supplement). Patients with CS after ET disclosed a higher incidence of delayed HT at follow-up neuroimaging compared with no-HA patients (OR, 3.1; 95% CI, 1.01-9.57; P=0.048) . This association remained significant in multivariate models adjusted by baseline Alberta Stroke Program Early CT Score, prior antithrombotic therapy, and cardioembolism (Table 2 ). Representative cases of delayed HT are shown in Figure 2 .
Discussion
The present study demonstrated a consistent association between post-ET BBB disruption, as evidenced by CS and BH on DE-CT images, and poor clinical outcomes. Moreover, the study also showed that the identification of isolated CS on DE-CT was a reliable harbinger of delayed HT. Collectively, these results supported the feasibility and clinical relevance of by guest on November 20, 2017 http://stroke.ahajournals.org/ Downloaded from DE-CT to identifying early BBB disruption in patients with acute stroke receiving ET.
In agreement with previous studies, signs of BBB disruption were found in ≈60% of patients. 3, 6, 7 However, the use of plain CT in most previous studies was a major drawback because of the limited ability of the technique to discriminate between CS and early HT. An intact BBB allows the passage of lipid-soluble molecules with molecular weights <400 Da. 19 Thus, the leakage in the brain tissue of iodinated contrast materials such as iopromide (a watersoluble molecule with a molecular weight of 791.12 Da) in patients without BH is consistent with early BBB disruption. Indeed, brain ischemia induces a time-dependent and gradual process of increased microvascular permeability that allows the leakage of a range of small molecules to larger cellular blood elements from microvessels into the extracellular space. 16, 17 As illustrated in Figure 1 , this gradual process of BBB disruption can be captured using DE-CT because of its ability to differentiate intracranial hemorrhage from isolated extravasation of iodinated contrast material.
In our series, both CS and early BH as classified by DE-CT were markers of poor clinical outcomes even despite complete recanalization in patients selected with the use of multimodal neuroimaging. 18 Moreover, the risk of delayed HT was increased in patients disclosing isolated CS in DE-CT. Overall, these data suggest that early BBB disruption is a predictor of poor outcomes and complement previous studies of BBB permeability using other neuroimaging strategies such as dynamic contrast-enhanced MR or CT imaging. 20, 21 Our data give further support to the potential role of therapies aimed to protect the BBB in combination with reperfusion therapies to heighten the chances of successful outcome after ET, in addition to strategies for improving the selection of patients to be treated and for shortening the time from stroke onset to complete reperfusion. 1 The pathophysiology of cerebral hemorrhage associated with reperfusion therapies involves the disruption of the BBB, procedure-related direct vessel damage, and the toxicity secondary to thrombolytic drugs. 22 In our series, the presence of signs of BBB disruption in DE-CT was associated with longer duration of the procedures and higher number of thrombectomy device passes, as well as with preintervention stroke severity and longer duration of ischemia. Longer procedure times were highly correlated with the number of passes of thrombectomy devices, as a marker of direct procedure-related vessel damage, and probably with enhanced exposure to intra-arterial contrast. The contribution of iodinated contrast material to the development of brain edema or HT is controversial. In experimental models of brain ischemia, intra-arterial administration of iodinated contrast material may increase intracerebral hemorrhage, 23 although this deleterious effect depends on the osmolarity of the contrast used. 24 In patients with acute stroke treated with intra-arterial alteplase, the number of microcatheter injections of contrast is related to an increase in the risk of intracranial hemorrhage, 
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The main strength of the study is that the use of DE-CT allowed us to investigate separately the prognostic relevance of isolated CS as an intermediate step between the absence of BBB disruption and early HT. Besides the role of DE-CT as a biomarker of BBB injury, the differentiation between CS and BH may be relevant to balance the risks and benefits of post-ET antithrombotic management. 9, 13 Nonetheless, the study has several limitations. First, the assessment of BBB disruption through the presence of high attenuation areas after ET is an indirect evaluation of a multifaceted and time-dependent process. 7, 26 Second, DE-CT has several technical limitations. 27 The presence of a fourth material (eg, calcium) other than normal brain parenchyma, iodine or blood, as well as certain artifacts (eg, metallic artifacts, beam hardening) may impair the discriminatory accuracy of the 3-material decomposition algorithm used in the image postprocessing, although this limitation was irrelevant in our series. Finally, the presence of high attenuation areas after ET was related to longer procedure times and to a shorter delay from procedure to the acquisition of DE-CT, although this limitation was addressed by including these 2 potentially confounding variables in the multivariate analysis for outcome prediction.
Conclusions
DE-CT allows an early grading of BBB disruption and adds relevant prognostic information in patients with acute stroke treated with ET. Moreover, DE-CT identifies a subgroup of patients with increased risk of delayed HT. These findings support the clinical relevance of early loss of BBB integrity after brain ischemia in patients with acute stroke treated endovascularly. ONLINE SUPPLEMENT.
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